Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity

J Neuroimmunol. 2002 Aug;129(1-2):197-204. doi: 10.1016/s0165-5728(02)00181-9.

Abstract

We studied the association between clinical outcome in MS and allelic variants single nucleotide polymorphisms (SNPs) of interleukin-1alpha (IL-1alpha), IL-1beta and a variable number tandem repeat (VNTR) in IL-1 receptor antagonist (IL-1RN). A total of 377 patients with MS were studied. Significant associations between IL-1 genotypes and clinical outcome were found using logistic regression after correction for gender, onset age and disease duration. The same trends were subsequently demonstrated in a second independent group of 67 primary progressive patients. Our results suggest that genetically determined immunomodulation mediated by IL-1 influences long-term prognosis in multiple sclerosis (MS).

MeSH terms

  • Adjuvants, Immunologic / genetics*
  • Adult
  • Age of Onset
  • Case-Control Studies
  • Disease Progression
  • Female
  • Gene Frequency / genetics
  • Genetic Predisposition to Disease / genetics*
  • Genotype
  • Homozygote
  • Humans
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1 / genetics*
  • Interleukin-1 / immunology
  • Linkage Disequilibrium / genetics
  • Male
  • Middle Aged
  • Multiple Sclerosis / genetics*
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / physiopathology
  • Polymorphism, Genetic / genetics*
  • Polymorphism, Genetic / immunology
  • Sex Factors
  • Sialoglycoproteins / genetics*
  • Sialoglycoproteins / immunology

Substances

  • Adjuvants, Immunologic
  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Sialoglycoproteins